The University of Pennsylvania Health System has announced a $25.5 million gift from Madlyn and Leonard Abramson to support basic science and translational research at the Abramson Family Cancer Research Institute.
Established twelve years ago, the institute is one of the nation's preeminent incubators for drug discovery and the development of new ways to diagnose and treat patients. The Abramsons' support has made possible the recruitment of twenty world-class scientists to the faculty of Penn Medicine; the establishment of new research programs in cancer cell metabolism, cancer vaccines, cell-based immunotherapy, and the study of the DNA repair system involved in breast cancer and lymphoma; genome-wide studies that have yielded new therapeutic targets for brain and kidney cancers; and blood and imaging tests to more easily diagnose certain cancers. With this latest gift, the Abramson family has provided more than $140 million in support to Penn Medicine.
"The advances in cancer research developed at Penn's Abramson Cancer Center have led to new prevention, diagnosis, and treatment programs that are awe-inspiring," said Arthur H. Rubenstein, executive vice president of the health system and dean of Penn's school of medicine. "By fostering the spirit of scientific inquiry, the Abramsons have enabled the most talented minds in the country to engage in the most advanced basic and translational research right here in Philadelphia."